- Home
- INKT vs TLPH Comparison
INKT vs TLPH Comparison
Compare INKT & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | TLPH |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.4M | 70.3M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | INKT | TLPH |
|---|---|---|
| Price | $10.45 | $1.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $42.50 | $3.13 |
| AVG Volume (30 Days) | 14.3K | ★ 103.3K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $44.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.48 | $0.69 |
| 52 Week High | $15.27 | $1.57 |
Technical Indicators
Market Signals| Indicator | INKT | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 35.33 |
| Support Level | $9.05 | $1.03 |
| Resistance Level | $12.27 | $1.04 |
| Average True Range (ATR) | 0.69 | 0.04 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 51.74 | 0.94 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.